Cara Therapeutics Stock News

Investors are likely to focus on Vertex Pharmaceuticals' (VRTX) CF product revenues, especially sales of its triple combo CF drug Trikafta/Kaftrio, and non-CF pipeline progress.

Zealand Pharma (ZEAL) completes patient enrollment in the phase III EASE-SBS 1 study evaluating glepaglutide for the potential treatment of short bowel syndrome.

The FDA clears CytomX's (CTMX) investigational new drug application for CX-904, which is being developed for the treatment of advanced solid tumors.

STAMFORD, Conn., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives

STAMFORD, Conn., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of

Cara received approval for IV KORSUVA in August. Since then, the stock has gone in circles without any catalysts to help unlock value.

Wall Street brokerages forecast that Cara Therapeutics, Inc. (NASDAQ:CARA) will post sales of $3.62 million for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Cara Therapeutics earnings, with the lowest sales estimate coming in at $150,000.00 and the highest estimate coming in at $8.60 million. Cara Therapeutics posted sales of []

KORSUVA receives TDAPA reimbursement beginning April 2022

Equities analysts expect Cara Therapeutics, Inc. (NASDAQ:CARA) to report ($0.50) earnings per share for the current quarter, according to Zacks. Three analysts have provided estimates for Cara Therapeutics earnings. The highest EPS estimate is ($0.42) and the lowest is ($0.60). Cara Therapeutics posted earnings of $1.59 per share during the same quarter last year, which []

Wells Fargo & Company MN lifted its position in Cara Therapeutics, Inc. (NASDAQ:CARA) by 53.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 223,861 shares of the biopharmaceutical companys stock after purchasing an additional 78,284 shares during the quarter. Wells Fargo & []

Della Vite, the Prosecco brand founded by celebrity sisters Cara, Poppy and Chloe Delevingne, launches in the EU just months after the brands expansion into the US, rounding off 2021 with a bang. The post Della Vite reflects on a year of growth and maturation as it expands into EU territories appeared first on The Drinks Business .

In last trading session, Cara Therapeutics Inc. (NASDAQ:CARA) saw 0.5 million shares changing hands with its beta currently measuring 1.04. Companys recent per share price level of $12.31 trading at -$0.58 or -4.50% at ring of the bell on the day assigns it a market valuation of $670.16M. That closing price of CARAs stock is Cara Therapeutics Inc. (NASDAQ:CARA) Currently -140.86% Below Its 52-Week High But The Downside Potential May Surprise You Read More »

NEW YORK, Nov. 30, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CARA, RDHL, BYSI, ATIP, and CODX. To see how InvestorsObserver''s proprietary scoring system rates these stocks, view the InvestorsObserver''s PriceWatch Alert by selecting the corresponding link….

Cara Diet Ampuh dan Cepat Full Power Method Continue reading on Medium »